Weight Loss

DALLAS — Adults with obesity who received tirzepatide for 72 weeks following a 12-week intensive lifestyle intervention achieved a total mean weight loss greater than 24%, according to data from the SURMOUNT-3 trial.

PHILADELPHIA — Midlife women with obesity should be counseled about anti-obesity medications and bariatric surgery in addition to diet, exercise and behavioral therapy for long-term weight-loss success, according to a speaker.

Adults with obesity receiving tirzepatide lost more than 25% of their body weight and were able to maintain their weight loss for up to 88 weeks, according to data from the SURMOUNT-4 trial.

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA.

The FDA has updated the label for Ozempic to include the potential risk for ileus, or an intestinal blockage, as well as increased risk for hypoglycemia if used in combination with insulin or insulin secretagogue.

Tirzepatide induced greater HbA1c and body weight reductions vs. placebo than semaglutide for people with type 2 diabetes, according to data that will be presented at the European Association for the Study of Diabetes annual meeting.

With reports of dramatic weight loss achieved using a new generation of diabetes drugs — one FDA approved for weight loss and another with a decision expected this fall — more adults are seeking medical therapy for obesity.

Researchers estimated that semaglutide could cut the obesity prevalence in the United States by about 46% and prevent more than 1.5 million CVD events over 10 years when given to eligible patients with overweight or obesity.

A new generation of obesity drugs is changing the treatment landscape for patients and providers, with options that can lead to weight loss unheard of just a few years ago.

Recent reports in the media and legal action have raised questions about the safety of popular weight-loss drugs, particularly about whether they increase the risk for events such as gastroparesis and gastroenteritis.